TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20220063

Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg/day
Number of subjects: 210

Group type: COMPARATOR
Intervention: Imatinib high dose or 400 mg + interferon-alpha
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Imatinib therapy
Number of subjects: 210
Study: 18684418

Group type: EXPERIMENTAL
Intervention: Usual care plus added pharmacist input
Number of subjects: 130

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 130
Study: 15562383

Group type: EXPERIMENTAL
Intervention: Transdermal estrogens (micronized 17beta‐estradiol; Systen, Janssen‐Cilag, Switzerland) and progesterone
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Oral hormones (Cyclo‐Menorette)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 61
Study: 12217138

Group type: EXPERIMENTAL
Intervention: Home telecare intervention
Number of subjects: 0
Study: 10359391

Group type: EXPERIMENTAL
Intervention: Androstenedione 300 mg/d (n = 10)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 30
Study: 7727473

Group type: EXPERIMENTAL
Intervention: Ganciclovir (5 mg/kg intravenously) given three times weekly for the first 6 weeks after transplantation and for another 2 weeks for each treated rejection episode between 6 and 12 weeks.
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Ganciclovir (10 mg/kg/day for 2 weeks)
Number of subjects: 56
Study: 1828447

Group type: EXPERIMENTAL
Intervention: Steroid therapy
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo or abstention
Number of subjects: 10
Study: 6816064

Group type: EXPERIMENTAL
Intervention: Misoprostol 200 micrograms
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Misoprostol 50 micrograms
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Misoprostol 100 micrograms
Number of subjects: 16
Study: 30337316

Group type: EXPERIMENTAL
Intervention: Nurse-led follow-up group
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 500
Study: 27677502

Group type: EXPERIMENTAL
Intervention: ALC-CHO (alcohol and carbohydrate)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: ALC-PRO (alcohol and protein)
Number of subjects: 8

Group type: COMPARATOR
Intervention: PRO (protein only)
Number of subjects: 8
Study: 24899662

Group type: EXPERIMENTAL
Intervention: Allopurinol treatment (10 patients treated for 4 weeks)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Patients with acute gout not receiving allopurinol
Number of subjects: 54

Group type: COMPARATOR
Intervention: All patient groups (including controls)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Controls and patients not receiving allopurinol
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: All patients receiving allopurinol
Number of subjects: 54
Study: 22565110

Group type: EXPERIMENTAL
Intervention: Intensive intervention group
Number of subjects: 2646

Group type: EXPERIMENTAL
Intervention: Moderately intensive intervention group
Number of subjects: 2646

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2646
Study: 20594432

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Individually randomised trials
Number of subjects: 73

Group type: COMPARATOR
Intervention: Cluster randomised trials
Number of subjects: 73

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 73
Study: 18567325

Group type: EXPERIMENTAL
Intervention: Cephalad orientation of spinal needle (group A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Lateral orientation of spinal needle (group B)
Number of subjects: 50
Study: 15812265

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 81

Group type: COMPARATOR
Intervention: Fluvoxamine
Number of subjects: 81
Study: 11922217

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma added to grafts
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group (grafts without platelet-rich plasma)
Number of subjects: 3
Study: 10937931

Group type: EXPERIMENTAL
Intervention: Bosentan therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metoprolol (beta-blocker)
Number of subjects: 0
Study: 8777826

Group type: EXPERIMENTAL
Intervention: Losartan potassium, 50 mg orally
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Enalapril, 20 mg orally
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combination of losartan and enalapril
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 1381788

Group type: EXPERIMENTAL
Intervention: cilazapril
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: nifedipine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: atenolol
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 6094451

Group type: EXPERIMENTAL
Intervention: 1.0 g cefotaxime before surgery
Number of subjects: 72

Group type: COMPARATOR
Intervention: 2.0 g cefoxitin pre-operatively and every 8 h for no more than 24 h post-operatively
Number of subjects: 72
Study: 31618706

Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood pressure (SMBP) intervention
Number of subjects: 158

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 158
Study: 29417920

Group type: COMPARATOR
Intervention: Standard protection
Number of subjects: 30

Group type: COMPARATOR
Intervention: Personal protective equipment (PPE)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Portable isolation unit (PIU)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Airway management difficulty rating (VAS 0-100) in PIU
Number of subjects: 30
Study: 27038786

Group type: EXPERIMENTAL
Intervention: i-Sleep (5-session guided online treatment)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Care-as-usual
Number of subjects: 160
Study: 27884184

Group type: EXPERIMENTAL
Intervention: Prudent diet
Number of subjects: 190

Group type: COMPARATOR
Intervention: Western diet
Number of subjects: 190
Study: 22743003

Group type: EXPERIMENTAL
Intervention: K-complex density
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Slow wave sleep (SWS) duration
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 20
Study: 20345617

Group type: EXPERIMENTAL
Intervention: Intravenous prostaglandin E1 (PGE) 60 microg in 100 mL saline
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (100 mL saline)
Number of subjects: 24
Study: 17910898

Group type: EXPERIMENTAL
Intervention: Abdominal muscle activation levels (biofeedback from the right external oblique muscle)
Number of subjects: 9
Study: 15991504

Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) ketamine 0.15 mg kg(‐1) before induction and 2 microg kg(‐1) min(‐1) during anaesthesia
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo administered in a similar manner
Number of subjects: 62
Study: 12762609

Group type: EXPERIMENTAL
Intervention: 5% Eutectic Mixture of Local Anesthetics (EMLA) cream applied for 3 minutes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 5% Eutectic Mixture of Local Anesthetics (EMLA) cream applied for 5 minutes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 5% Eutectic Mixture of Local Anesthetics (EMLA) cream applied for 10 minutes
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo applied for 3, 5, or 10 minutes
Number of subjects: 20
Study: 10477166

Group type: COMPARATOR
Intervention: Granisetron 3 mg i.m. daily (plus placebo)
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: Granisetron 3 mg i.m. daily plus dexamethasone 8 and 4 mg twice daily
Number of subjects: 532
Study: 9097713

Group type: EXPERIMENTAL
Intervention: BrdUrd LI
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: AgNOR technique
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: S-phase fraction (SPF)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Aneuploid tumours
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: AgNOR counts
Number of subjects: 37
Study: 1921674

Group type: EXPERIMENTAL
Intervention: Mixed-snick food (CB)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Fructose (FRU)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 8
Study: 6387892

Group type: EXPERIMENTAL
Intervention: Cephalexin (25-50 mg/kg body weight per day for 3 days)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Nitrofurantoin (3-4 mg/kg/day for 10 days)
Number of subjects: 43
Study: 31808408

Group type: EXPERIMENTAL
Intervention: Physical therapy (Group 2) - Two pre-RP physical therapist-guided PFMT sessions, including exercises and electromyographic biofeedback, and verbal and written instructions to continue PFMT until RP, which was then resumed after urethral catheter removal.
Number of subjects: 31

Group type: COMPARATOR
Intervention: Usual post-RP care (Group 1) - Control group receiving standard care after RP.
Number of subjects: 31
Study: 30017370

Group type: EXPERIMENTAL
Intervention: Pharmacist-led transitions-of-care pilot
Number of subjects: 34
Study: 27588816

Group type: EXPERIMENTAL
Intervention: AndoSan™
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 24870716

Group type: EXPERIMENTAL
Intervention: Seeing the back during tactile acuity testing
Number of subjects: 0
Study: 22174437

Group type: COMPARATOR
Intervention: Pravastatin (40 mg) administered alone on day 4
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg) administered with darunavir/ritonavir (600/100 mg) on days 15-18
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Group 3 variants (SLCO1B1*15 and *17)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Comparison of SLCO1B1 diplotype groups
Number of subjects: 32
Study: 19954944

Group type: EXPERIMENTAL
Intervention: Exercise (60 min of treadmill walking, estimated 55% VO2 peak)
Number of subjects: 9

Group type: COMPARATOR
Intervention: No exercise (rest)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 9
Study: 18246859

Group type: EXPERIMENTAL
Intervention: Agomelatine (Valdoxan)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other antidepressant drugs
Number of subjects: 0
Study: 17146693

Group type: EXPERIMENTAL
Intervention: Power Training (PT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional Resistance Training (TRT)
Number of subjects: 20
Study: 15027055

Group type: EXPERIMENTAL
Intervention: BoNT/A (BOTOX 15MU)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: BoNT/B (NeuroBloc 1500MU)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: BoNT/F (15MU)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: BoNT/C (15MU)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 12
Study: 11908406

Group type: EXPERIMENTAL
Intervention: 5.3% hydrogen peroxide whitening strip
Number of subjects: 36

Group type: COMPARATOR
Intervention: 10% carbamide peroxide tray-based bleaching system
Number of subjects: 36

Group type: COMPARATOR
Intervention: 15% carbamide peroxide tray-based bleaching system
Number of subjects: 36

Group type: COMPARATOR
Intervention: 20% carbamide peroxide tray-based bleaching system
Number of subjects: 36
Study: 9051281

Group type: EXPERIMENTAL
Intervention: Cognitive restructuring, interoceptive exposure, and in vivo exposure
Number of subjects: 38

Group type: COMPARATOR
Intervention: Cognitive restructuring, breathing retraining, and in vivo exposure
Number of subjects: 38
Study: 7921798

Group type: EXPERIMENTAL
Intervention: 19% hydrogen peroxide solution
Number of subjects: 23

Group type: COMPARATOR
Intervention: 35% hydrogen peroxide solution
Number of subjects: 23
Study: 3713101

Group type: EXPERIMENTAL
Intervention: i.v. immunoglobulin (4 X 100 ml) combined with antibiotics
Number of subjects: 104

Group type: COMPARATOR
Intervention: antibiotics alone
Number of subjects: 104
Study: 30968258

Group type: EXPERIMENTAL
Intervention: Cefotaxime 100–150 mg/kg/day
Number of subjects: 37
Study: 28523596

Group type: EXPERIMENTAL
Intervention: Vismodegib 150 mg daily
Number of subjects: 31
Study: 25857271

Group type: EXPERIMENTAL
Intervention: Plant stanol group (n=46) consuming vegetable-oil spread enriched with plant stanols 3 g/day for 6 months
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (n=46) consuming vegetable-oil spread not enriched with plant stanols
Number of subjects: 92
Study: 23975226

Group type: EXPERIMENTAL
Intervention: Denosumab 120 mg
Number of subjects: 2620

Group type: COMPARATOR
Intervention: Zoledronic acid 4 mg
Number of subjects: 2620
Study: 21427402

Group type: EXPERIMENTAL
Intervention: Abacavir therapy
Number of subjects: 5056

Group type: COMPARATOR
Intervention: No abacavir therapy
Number of subjects: 5056
Study: 19773678

Group type: EXPERIMENTAL
Intervention: Surgical excision of the involved lymph nodes
Number of subjects: 100

Group type: COMPARATOR
Intervention: Antibiotic therapy (clarithromycin and rifabutin)
Number of subjects: 100
Study: 17105794

Group type: EXPERIMENTAL
Intervention: Tolterodine ER plus tamsulosin
Number of subjects: 878

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 878

Group type: COMPARATOR
Intervention: Tamsulosin
Number of subjects: 878

Group type: COMPARATOR
Intervention: Tolterodine ER
Number of subjects: 878
Study: 15221494

Group type: EXPERIMENTAL
Intervention: Alfacalcidol 1 micro g/day with calcium for 6 months
Number of subjects: 80

Group type: COMPARATOR
Intervention: Calcium (control group)
Number of subjects: 80
Study: 11592566

Group type: EXPERIMENTAL
Intervention: Growth hormone therapy at a dose of 1.5 mg/m2/day
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Growth hormone therapy at a dose of 0.3 mg/m2/day
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Growth hormone therapy (any dose)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Growth hormone therapy at a dose of >0.3 mg/m2/day
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Growth hormone therapy at a dose of <0.3 mg/m2/day
Number of subjects: 46
Study: 10345909

Group type: EXPERIMENTAL
Intervention: Health education intervention for children and parents over 3 years
Number of subjects: 962
Study: 7978145

Group type: EXPERIMENTAL
Intervention: Thiopentone 100 mg
Number of subjects: 115

Group type: COMPARATOR
Intervention: Lignocaine 20 mg
Number of subjects: 115

Group type: COMPARATOR
Intervention: Intravenous saline 4 ml
Number of subjects: 115
Study: 2659747

Group type: EXPERIMENTAL
Intervention: Intermittent cisplatin (CDDP 60 mg/m2 day 1 and VP16 120 mg/m2 day 1‐3 every 3‐4 weeks)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Weekly cisplatin (CDDP 20 mg/m2 and VP16 120 mg/m2)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 55
Study: 31704781

Group type: EXPERIMENTAL
Intervention: 2019 authorship practices evaluation
Number of subjects: 26

Group type: COMPARATOR
Intervention: Comparison with 2003 data
Number of subjects: 26
Study: 30525235

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.025%
Number of subjects: 117

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 117

Group type: COMPARATOR
Intervention: Brimonidine 0.025% and Vehicle
Number of subjects: 117
Study: 28866621

Group type: EXPERIMENTAL
Intervention: Just-in-Time (JIT) intervention using a portable, bedside computer-based procedural adjunct
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no JIT intervention)
Number of subjects: 0
Study: 25924030

Group type: EXPERIMENTAL
Intervention: Preoperative sedimentation rate <20 mm/h (normal)
Number of subjects: 363

Group type: COMPARATOR
Intervention: Preoperative sedimentation rate >20 mm/h (above normal)
Number of subjects: 363
Study: 23535740

Group type: EXPERIMENTAL
Intervention: High fiber (HF) diet consisting of oat bran, rye bran, and sugar beet fiber
Number of subjects: 25

Group type: COMPARATOR
Intervention: Low fiber (LF) diet made of equivalent food products to the HF diet, but without adding fibers
Number of subjects: 25
Study: 21765364

Group type: EXPERIMENTAL
Intervention: Urine lipoarabinomannan (LAM) test
Number of subjects: 422

Group type: COMPARATOR
Intervention: Gold standard (positive bacteriology or histopathology)
Number of subjects: 422
Study: 19335346

Group type: EXPERIMENTAL
Intervention: Truview infant EVO2 laryngoscope
Number of subjects: 60

Group type: COMPARATOR
Intervention: Miller blade number 0
Number of subjects: 60
Study: 17326999

Group type: EXPERIMENTAL
Intervention: D-IBS patients
Number of subjects: 26

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 26
Study: 15513250

Group type: EXPERIMENTAL
Intervention: Object-based selection processes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Space-based selection processes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of space-based and object-based manipulations
Number of subjects: 0
Study: 11333840

Group type: EXPERIMENTAL
Intervention: High-Carbohydrate Diet (HC diet)
Number of subjects: 7

Group type: COMPARATOR
Intervention: High-Fat Diet (HF diet)
Number of subjects: 7
Study: 9260010

Group type: EXPERIMENTAL
Intervention: 5 mg.kg‐1 thiopentone iv, isoflurane/N2O maintenance
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: 3 mg.kg‐1 propofol iv, propofol/N2O maintenance (10‐14 mg.kg‐1.hr‐1)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: 3 mg.kg‐1 propofol iv, propofol/air/O2 maintenance (10‐14 mg.kg‐1.hr‐1)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Thiopentone-isoflurane
Number of subjects: 97
Study: 8288071

Group type: EXPERIMENTAL
Intervention: Withdrawal of diuretic therapy
Number of subjects: 15
Study: 3548734

Group type: EXPERIMENTAL
Intervention: fenofibrate 300 mg/day
Number of subjects: 33

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 33
Study: 29625879

Group type: EXPERIMENTAL
Intervention: Tivantinib (120 mg twice daily)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Placebo (twice daily)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Tivantinib
Number of subjects: 340

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340
Study: 28662956

Group type: EXPERIMENTAL
Intervention: Topical TXA (tTXA)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Systemic TXA (sTXA)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study: 26586317

Group type: EXPERIMENTAL
Intervention: Chiropractic spinal manipulative therapy (CSMT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (sham manipulation)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (usual non-manual management)
Number of subjects: 90
Study: 23007223

Group type: EXPERIMENTAL
Intervention: Silverhawk atherectomy
Number of subjects: 19

Group type: COMPARATOR
Intervention: Percutaneous transluminal angioplasty (PTA)
Number of subjects: 19
Study: 21247887

Group type: EXPERIMENTAL
Intervention: 3-month strength-training programme
Number of subjects: 150
Study: 18444945

Group type: EXPERIMENTAL
Intervention: ABCB1 2677T allele
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: IMPDH2 3757C allele
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: IL-10 -592A homozygous
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: TNF-alpha G-308A with at least one A allele
Number of subjects: 237
Study: 16596905

Group type: EXPERIMENTAL
Intervention: Insemination cycles with abnormal seminal viscosity (group I)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Insemination cycles with normal semen viscosity (group II)
Number of subjects: 37
Study: 12611749

Group type: EXPERIMENTAL
Intervention: Morning bright light
Number of subjects: 92

Group type: COMPARATOR
Intervention: Morning dim red light
Number of subjects: 92

Group type: COMPARATOR
Intervention: Evening bright light
Number of subjects: 92
Study: 11382894

Group type: EXPERIMENTAL
Intervention: GHRH (4x50 microgram, at hourly intervals between 2200 and 0100 h)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (matched controls)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: GHRH treatment
Number of subjects: 75
Study: 9149741

Group type: EXPERIMENTAL
Intervention: Etoposide (ETOP), Ifosfamide (IFOS), and Vincristine (VCR) with hyperfractionated radiation therapy (XRT)
Number of subjects: 68
Study: 7957372

Group type: EXPERIMENTAL
Intervention: Single dose oral steroids (oral prednisone: 20‐40 mg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 3296841

Group type: EXPERIMENTAL
Intervention: Methylprednisolone pulse therapy (MPPT) (1000 mg daily for 3 days)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Standard doses of methylprednisolone (MP) (50 mg daily gradually decreased to zero over 3 weeks)
Number of subjects: 6
Study: 30902672

Group type: EXPERIMENTAL
Intervention: Intermittent energy restriction (2100-2500 kJ [500-600 kcal] diet 2 non-consecutive days/week)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Continuous energy restriction (5000-6300 kJ [1200-1500 kcal] diet 7 days/week)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 137
Study: 28745667

Group type: EXPERIMENTAL
Intervention: Cytoflavin (20 ml in 200 ml of 5% glucose solution)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 26521499

Group type: EXPERIMENTAL
Intervention: Debriefing for Meaningful Learning (DML)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual and customary debriefing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison between DML and usual debriefing
Number of subjects: 0
Study: 22903547

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Diet supplemented with 5% fish oil (high in EPA and DHA)
Number of subjects: 2
Study: 21560158

Group type: EXPERIMENTAL
Intervention: fesoterodine 4 mg
Number of subjects: 883

Group type: EXPERIMENTAL
Intervention: fesoterodine 8 mg
Number of subjects: 883

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 883
Study: 18635306

Group type: EXPERIMENTAL
Intervention: Simplified protocol with instruction to 'push as hard as you can'
Number of subjects: 332

Group type: COMPARATOR
Intervention: MPDS protocol with instruction to 'push down firmly 2in. (5cm)'
Number of subjects: 332
Study: 17151163

Group type: EXPERIMENTAL
Intervention: Internet-based bibliotherapy self-help program with short weekly telephone calls
Number of subjects: 60

Group type: COMPARATOR
Intervention: Wait-listed control group
Number of subjects: 60
Study: 12675461

Group type: EXPERIMENTAL
Intervention: Conventional heat-cured acrylic resin dentures
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Rapid heat-cured acrylic resin dentures
Number of subjects: 17